Glenmark introduces NINDANIB - Angel Broking

Mr. Yash Gupta - Equity Research Associate, Angel Broking Ltd

"Glenmark introduces NINDANIB (Nintedanib) and is amongst the first to launch the branded generic version at an affordable cost for the treatment of Pulmonary Fibrosis in India . Pulmonary fibrosis (PF) is a respiratory condition characterized by thickening and/or scarring of the lungs, making breathing difficult and reducing patient life spans Idiopathic Pulmonary Fibrosis affects as many as 120 Indians per million Patients with IPF are at higher risk of developing severe respiratory conditions if affected by COVID-19 Glenmark's NINDANIB priced at Rs. 4500 (100 mg) and Rs. 5400 (150 mg) PER MONTH is just available at 5 % of the cost as compared to the innovator brand in India. This is a very positive development for the company."

Shares of GLENMARK PHARMACEUTICALS LTD. was last trading in BSE at Rs.485.8 as compared to the previous close of Rs. 490.95. The total number of shares traded during the day was 147608 in over 4142 trades.

The stock hit an intraday high of Rs. 496.4 and intraday low of 471.8. The net turnover during the day was Rs. 71424071.

Source : Equity Bulls

Keywords